DE69942176D1 - CHOLINE-BINDING PROTEIN DERIVATIVES FROM PNEUMOCOKES AS A VACCINE - Google Patents

CHOLINE-BINDING PROTEIN DERIVATIVES FROM PNEUMOCOKES AS A VACCINE

Info

Publication number
DE69942176D1
DE69942176D1 DE69942176T DE69942176T DE69942176D1 DE 69942176 D1 DE69942176 D1 DE 69942176D1 DE 69942176 T DE69942176 T DE 69942176T DE 69942176 T DE69942176 T DE 69942176T DE 69942176 D1 DE69942176 D1 DE 69942176D1
Authority
DE
Germany
Prior art keywords
vaccine
choline
pneumocokes
binding protein
protein derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69942176T
Other languages
German (de)
Inventor
Theresa M Wizemann
Scott Koenig
Leslie S Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Application granted granted Critical
Publication of DE69942176D1 publication Critical patent/DE69942176D1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)

Abstract

The present invention provides bacterial immunogenic agents for administration to humans and non-human animals to stimulate an immune response. It particularly relates to the vaccination of mammalian species with pneumococcal derived polypeptides that include an alpha helix but exclude a choline binding region as a mechanism for stimulating production of antibodies that protect the vaccine recipient against infection by pathogenic bacterial species. In another aspect the invention provides antibodies against such proteins and protein complexes that may be used as diagnostics and/or as protective/treatment agents for pathogenic bacterial species.
DE69942176T 1998-04-07 1999-04-06 CHOLINE-BINDING PROTEIN DERIVATIVES FROM PNEUMOCOKES AS A VACCINE Expired - Lifetime DE69942176D1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8087898P 1998-04-07 1998-04-07
US8574398P 1998-05-15 1998-05-15
PCT/US1999/007680 WO1999051266A2 (en) 1998-04-07 1999-04-06 Derivatives of pneumococcal choline binding proteins for vaccines

Publications (1)

Publication Number Publication Date
DE69942176D1 true DE69942176D1 (en) 2010-05-06

Family

ID=26764078

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69942176T Expired - Lifetime DE69942176D1 (en) 1998-04-07 1999-04-06 CHOLINE-BINDING PROTEIN DERIVATIVES FROM PNEUMOCOKES AS A VACCINE

Country Status (16)

Country Link
US (3) US6503511B1 (en)
EP (1) EP1067962B1 (en)
JP (1) JP2002510649A (en)
KR (2) KR100794394B1 (en)
CN (1) CN1200731C (en)
AT (1) ATE461709T1 (en)
AU (1) AU766455C (en)
BR (1) BR9909483A (en)
CA (1) CA2325340A1 (en)
DE (1) DE69942176D1 (en)
ES (1) ES2343492T3 (en)
HU (1) HUP0102617A3 (en)
IL (2) IL138798A0 (en)
NO (1) NO20004972L (en)
NZ (2) NZ507717A (en)
WO (1) WO1999051266A2 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078042B2 (en) * 1995-09-15 2006-07-18 Uab Research Foundation Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
NZ507717A (en) * 1998-04-07 2004-02-27 Medimmune Inc Derivatives of pneumococcal choline binding proteins for vaccines
KR100638503B1 (en) * 1998-04-07 2006-10-26 세인트 쥬드 칠드런즈 리써치 호스피탈 A polypetide comprising the amino acid of an N-terminal choline binding protein A truncate, vaccine derived therefrom and pharmaceutical composition comprising the same
US6858706B2 (en) 1998-04-07 2005-02-22 St. Jude Children's Research Hospital Polypeptide comprising the amino acid of an N-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
US7128918B1 (en) * 1998-12-23 2006-10-31 Id Biomedical Corporation Streptococcus antigens
EP2277535A3 (en) 1999-03-19 2011-03-09 GlaxoSmithKline Biologicals SA Vaccine
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
AU2001287645A1 (en) * 2000-07-20 2002-02-05 Hansa Medical Ab Fh-binding protein of streptococcus pneumiae
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
US6674504B1 (en) 2000-09-29 2004-01-06 Kent Optronics, Inc. Single layer multi-state ultra-fast cholesteric liquid crystal device and the fabrication methods thereof
ES2408251T3 (en) 2002-08-02 2013-06-19 Glaxosmithkline Biologicals S.A. Neisseria vaccine compositions comprising a combination of antigens
BR0315767A (en) 2002-11-01 2005-09-06 Glaxosmithkline Biolog Sa Immunogenicity composition, method for making a vaccine, kit, vaccine, container with a water repellent inner surface, and method for preserving a composition comprising ipv and a stabilizing agent
DE602004028262D1 (en) 2003-10-02 2010-09-02 Glaxosmithkline Biolog Sa B. PERTUSSIS ANTIGENE AND ITS USE IN VACCINATION
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
US8052971B2 (en) * 2005-11-21 2011-11-08 MG Biologics Oral use of specific antibodies for intestinal health
TWI457133B (en) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa Novel composition
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
NZ596500A (en) 2005-12-22 2013-05-31 Glaxosmithkline Biolog Sa Pneumococcal polysaccharide conjugate vaccine
NZ569417A (en) 2006-01-17 2012-04-27 Arne Forsgren A novel surface exposed haemophilus influenzae protein (protein E; pE)
WO2008039838A2 (en) 2006-09-27 2008-04-03 St. Jude Children's Research Hospital Synthetic streptococcus pneumoniae vaccine
ES2626662T3 (en) 2007-06-26 2017-07-25 Glaxosmithkline Biologicals S.A. Vaccine comprising capsular polysaccharide conjugates of Streptococcus pneumoniae
JP5056490B2 (en) * 2008-03-10 2012-10-24 富士通株式会社 Distortion compensation coefficient updating apparatus and distortion compensation amplifier
RS54306B1 (en) 2008-04-16 2016-02-29 Glaxosmithkline Biologicals S.A. Vaccine
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
BR112012022669A2 (en) 2010-03-10 2017-02-14 Glaxosmithkline Biologicals Sa immunogenic composition, method of treating or preventing infection or disease, use of an antigen, kit, methods for making an immunogenic composition and for improving a vaccine.
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
US10913781B2 (en) 2011-04-08 2021-02-09 Tufts Medical Center, Inc. Pepducin design and use
MX339058B (en) 2011-05-17 2016-05-09 Glaxosmithkline Biolog Sa Vaccine against streptococcus pneumoniae.
JP2014000016A (en) * 2012-06-15 2014-01-09 National Agriculture & Food Research Organization Novel antigenic protein of erysipelothrix rhusiopathiae, gene thereof, recombinant vector, and the use thereof
GB201318170D0 (en) * 2013-10-14 2013-11-27 Univ Edinburgh Proteins with Diagnostic and Therapeutic Uses
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
US11091533B2 (en) 2015-11-13 2021-08-17 Oasis Pharmaceuticals, LLC Protease-activated receptor-2 modulators
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
JP7132954B2 (en) 2017-06-10 2022-09-07 インベントプライズ リミテッド ライアビリティ カンパニー Multivalent conjugate vaccines comprising bivalent or multivalent conjugated polysaccharides providing improved immunogenicity and avidity
GB201714478D0 (en) * 2017-09-08 2017-10-25 Univ Bristol Sensor
US12053515B2 (en) 2020-08-10 2024-08-06 Inventprise, Inc. Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24F

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
US5980909A (en) * 1991-02-15 1999-11-09 Uab Research Foundation Epitopic regions of pneumococcal surface protein A
US6232116B1 (en) * 1991-02-15 2001-05-15 University Of Alabama At Birmingham Research Foundation Oral administration of pneumococcal antigens
US6027734A (en) * 1991-02-15 2000-02-22 Uab Research Foundation Mucosal administration of pneumococcal antigens
US6231870B1 (en) * 1995-06-02 2001-05-15 Uab Research Foundation Oral administration of pneumoccal antigens
US6042838A (en) * 1991-02-15 2000-03-28 Uab Research Foundation immunogenic compositions for mucosal administration of pneumococcal surface protein A (PspA)
US7078042B2 (en) * 1995-09-15 2006-07-18 Uab Research Foundation Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
ES2262177T3 (en) * 1996-05-01 2006-11-16 The Rockefeller University PROTEINS OF UNION TO HILL FOR VACCINES AGAINST NEUMOCOCOS.
US6245335B1 (en) * 1996-05-01 2001-06-12 The Rockefeller University Choline binding proteins for anti-pneumococcal vaccines
EP0941335A2 (en) * 1996-10-31 1999-09-15 Human Genome Sciences Streptococcus pneumoniae polynucleotides and sequences
CA2270898A1 (en) * 1996-11-06 1998-05-14 The Regents Of The University Of California Isolated tumor necrosis factor receptor releasing enzyme, compositions comprising the enzyme and methods of the use thereof
WO1998021337A2 (en) * 1996-11-12 1998-05-22 Regents Of The University Of Minnesota C3 BINDING PROTEIN OF $i(STREPTOCOCCUS PNEUMONIAE)
DE19708537A1 (en) 1997-03-03 1998-09-10 Biotechnolog Forschung Gmbh New surface protein (SpsA protein) from Streptococcus pneumoniae etc.
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
NZ507717A (en) * 1998-04-07 2004-02-27 Medimmune Inc Derivatives of pneumococcal choline binding proteins for vaccines
US6858706B2 (en) * 1998-04-07 2005-02-22 St. Jude Children's Research Hospital Polypeptide comprising the amino acid of an N-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
US6936252B2 (en) * 1998-07-27 2005-08-30 Microbial Technics Limited Streptococcus pneumoniae proteins and nucleic acid molecules
DK1140157T3 (en) * 1998-12-21 2009-06-08 Medimmune Inc Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
AU2001255772B2 (en) * 2000-04-27 2006-06-29 Medimmune, Llc Immunogenic pneumococcal protein and vaccine compositions thereof
EP2921924B1 (en) * 2014-03-21 2018-09-19 Asco Numatics GmbH Device for providing a fluid with controlled output pressure
US9741151B2 (en) * 2015-04-14 2017-08-22 International Business Machines Corporation Mobile interactive comparison chart

Also Published As

Publication number Publication date
CA2325340A1 (en) 1999-10-14
NZ507717A (en) 2004-02-27
US20050142145A1 (en) 2005-06-30
NO20004972L (en) 2000-12-05
AU3386999A (en) 1999-10-25
ES2343492T3 (en) 2010-08-02
KR20010034752A (en) 2001-04-25
IL138798A (en) 2008-11-03
BR9909483A (en) 2001-10-09
NO20004972D0 (en) 2000-10-03
KR20060126844A (en) 2006-12-08
US6503511B1 (en) 2003-01-07
WO1999051266A2 (en) 1999-10-14
EP1067962B1 (en) 2010-03-24
WO1999051266A3 (en) 1999-12-09
JP2002510649A (en) 2002-04-09
CN1315870A (en) 2001-10-03
EP1067962A2 (en) 2001-01-17
AU766455B2 (en) 2003-10-16
KR100794394B1 (en) 2008-01-15
US7435421B2 (en) 2008-10-14
CN1200731C (en) 2005-05-11
HUP0102617A2 (en) 2001-11-28
US6863893B2 (en) 2005-03-08
IL138798A0 (en) 2001-10-31
AU766455C (en) 2004-12-02
US20030138447A1 (en) 2003-07-24
ATE461709T1 (en) 2010-04-15
NZ530277A (en) 2005-08-26
HUP0102617A3 (en) 2006-04-28

Similar Documents

Publication Publication Date Title
DE69942176D1 (en) CHOLINE-BINDING PROTEIN DERIVATIVES FROM PNEUMOCOKES AS A VACCINE
DK0950068T3 (en) Collagen-binding protein compositions and methods of use
WO2002004496A3 (en) Fimh adhesin proteins and methods of use
WO2002102974A3 (en) Mutant proteins, high potency inhibitory antibodies and fimch crystal structure
EA200201280A1 (en) Streptokokovye antigens
NL300897I2 (en) Neisseira meningitidis serogroup B recombinantly lipidated fHbp subfamily A05 protein
NZ512574A (en) Novel streptococcus antigens useful as vaccines
CY1105221T1 (en) MEDICINAL USE OF THYROIDOMIMETIC COMPOUNDS FOR THE THERAPEUTIC TREATMENT OF HAIR LOSS AND PHARMACEUTICAL COMPOSITIONS
ATE314095T1 (en) VIRUS-LIKE PARTICLES FOR INDUCING AUTOANTIBODIES
CY1107571T1 (en) NURSING GROWTH FACTOR AS Auxiliary Vaccine
TW200507874A (en) Immunostimulatory nucleic acid oil-in-water formulations and related methods of use
DE602004013993D1 (en) R FOR BIOLOGICAL ACTIVE SUBSTANCE FOR ORAL ADMINISTRATION
DE602004028029D1 (en) Rwendung
DE69833876D1 (en) COMPOSITIONS AND METHODS FOR TARGETED DELIVERY OF BIOLOGICAL ACTIVE FACTORS
BR0109928A (en) Use of an attenuated herpes virus, and, method for stimulating an immune response in a human or animal individual, or for treating or preventing a pathogenic infection or cancer in a human or animal individual.
ATE367806T1 (en) MEANS AND METHODS FOR PREVENTING CHEMOTHERAPY-induced AOPEZIA
GB9723945D0 (en) Tissue cement
DE69833568D1 (en) ISOLATED STRAINS OF STAPHYLOCOCCUS AUREUS AND VACCINES MANUFACTURED THEREOF
TR200003722T2 (en) Pneumococcal choline-binding protein derivatives for vaccines
ATE353226T1 (en) ADJUVANT COMPOSITION CONTAINING FHA OR AN FHA FRAGMENT IN FREE FORM
WO2000077177A3 (en) Isolation of a human retrovirus
CY1108761T1 (en) DISABILIZED CATS FOR IMMUNIZATION
BR0110791A (en) Composition, methods for inducing an individual immune response against an immunogen, modulating an individual's immune system and immunizing an individual against a live attenuated pathogen, recombinant vaccine, and pathogen
WO2024130155A3 (en) Swine influenza vaccine compositions and methods thereof
BR0012740A (en) Compounds for the treatment of infectious and immune system disorders and methods for their use

Legal Events

Date Code Title Description
8364 No opposition during term of opposition